Oral Presentations 5 TDM in Neurology

17:00 • 738 • Pharmacogenetic determinants of interindividual variability in sertraline exposure and tolerability in patients with depression > L. Lana Ganoci 17:13 • 491 • Stratified therapeutic drug monitoring could potentially improve efficacy and safety of oxcarbazepine in children with epilepsy: Novel insights from a single-center, large-sample, retrospective real-world study > F. Feng Chen 17:26 • 438 • Does early CYP2C19 and CYP2D6 genotyping reduce the risk of venlafaxine treatment failure? > E. Espen MOLDEN 17:39 • 166 • From Summary of Product Characteristics (SmPC) recommendations to clinical practice: Is pharmacogenetics documented in serious adverse drug reactions to psychotropic drugs? > F. Florent Voillet 17:52 • 528 • Impact of body mass index and body surface area on perampanel concentration-to-dose ratio in children with epilepsy: A real-world study > H. Hongai Pan 18:05 • 359 • Therapeutic Drug Monitoring of Lurasidone in Clinical Practice: Evaluation of Therapeutic Ranges and the Impact of Patient-Specific Factors on Plasma Concentrations > S. Séverine Crettol 18:18 • 322 • Individualized Dosing Study of Lamotrigine Based on Blood Concentration Monitoring and Genetic Testing > Y. Yinghong Wang